| Size | Price | Stock | Qty |
|---|---|---|---|
| 1g |
|
||
| 5g |
|
||
| Other Sizes |
| Targets |
No direct biological target; the compound is a phosphoramidite building block for oligonucleotide synthesis. The 2'-O-MOE modification, when incorporated into oligonucleotides, enhances nuclease resistance, increases binding affinity to complementary RNA, and improves pharmacokinetic properties. The DMT group protects the 5'-hydroxyl during synthesis, and the Bz group protects the adenine amino group.
|
|---|---|
| ln Vitro |
The compound itself has no biological activity as it is a synthetic building block. Upon incorporation into oligonucleotides (e.g., antisense oligonucleotides, siRNAs), the 2'-O-MOE modification enhances nuclease resistance, improves target binding affinity, and increases metabolic stability. Oligonucleotides containing this modification are used in therapeutic and research applications.
|
| ln Vivo |
Not applicable; the compound is a synthetic building block with no direct in vivo activity. Oligonucleotides synthesized using this phosphoramidite may have in vivo activity depending on the sequence and target. The 2'-O-MOE modification improves the pharmacokinetic properties of oligonucleotides.
|
| Enzyme Assay |
Not applicable for the phosphoramidite. For oligonucleotide synthesis, standard solid-phase phosphoramidite chemistry is used. The compound is coupled to a growing oligonucleotide chain, oxidized, and capped. After synthesis, the oligonucleotide is deprotected and purified. The final product is characterized by HPLC, mass spectrometry, and other methods.
|
| Cell Assay |
Cells are not typically treated directly with this phosphoramidite. The compound is used in chemical synthesis of modified oligonucleotides. The final oligonucleotides may be tested in cellular assays for target knockdown, nuclease resistance, and biological activity.
|
| Animal Protocol |
Not applicable; the compound is a synthetic building block not used directly in animal studies. Oligonucleotides synthesized using this phosphoramidite may be tested in animal models for therapeutic applications such as antisense therapy. The 2'-O-MOE modification improves oligonucleotide stability and PK properties.
|
| ADME/Pharmacokinetics |
Pharmacokinetic data for the phosphoramidite are not applicable. Oligonucleotides containing 2'-O-MOE modifications have improved pharmacokinetic properties, including increased nuclease resistance, longer half-life, and better tissue distribution. The DMT and Bz groups are removed during synthesis and do not affect the final oligonucleotide's PK.
|
| Toxicity/Toxicokinetics |
Toxicology data for the phosphoramidite have not been published. The compound is for research use only and not approved for human therapeutic applications. No systematic toxicological evaluation has been performed. Standard safety precautions for handling chemical intermediates should be observed.
|
| References | |
| Additional Infomation |
DMT-2'-O-MOE-rA(Bz) phosphoramidite (CAS: 251647-53-7) is a protected RNA phosphoramidite. It features 5'-O-DMT, 2'-O-MOE, N6-benzoyl protection, and 3'-phosphoramidite. It is used in oligonucleotide synthesis for antisense and RNAi applications. It is not in clinical trials and has no regulatory approval. The compound is supplied as a research-grade phosphoramidite for laboratory use only.
|
| Molecular Formula |
C49H56N7O9P
|
|---|---|
| Molecular Weight |
917.98
|
| Exact Mass |
931.403
|
| CAS # |
251647-53-7
|
| PubChem CID |
137706485
|
| Appearance |
White to off-white solid powder
|
| LogP |
10.19
|
| Hydrogen Bond Donor Count |
1
|
| Hydrogen Bond Acceptor Count |
14
|
| Rotatable Bond Count |
23
|
| Heavy Atom Count |
67
|
| Complexity |
1490
|
| Defined Atom Stereocenter Count |
0
|
| InChi Key |
VPBYBQBHLYRLHG-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C50H58N7O9P/c1-34(2)57(35(3)4)67(64-28-14-27-51)66-44-42(31-63-50(37-17-12-9-13-18-37,38-19-23-40(60-6)24-20-38)39-21-25-41(61-7)26-22-39)65-49(45(44)62-30-29-59-5)56-33-54-43-46(52-32-53-47(43)56)55-48(58)36-15-10-8-11-16-36/h8-13,15-26,32-35,42,44-45,49H,14,28-31H2,1-7H3,(H,52,53,55,58)
|
| Chemical Name |
N-[9-[5-[[bis(4-methoxyphenyl)-phenylmethoxy]methyl]-4-[2-cyanoethoxy-[di(propan-2-yl)amino]phosphanyl]oxy-3-(2-methoxyethoxy)oxolan-2-yl]purin-6-yl]benzamide
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment (e.g. under nitrogen), avoid exposure to moisture. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.0893 mL | 5.4467 mL | 10.8935 mL | |
| 5 mM | 0.2179 mL | 1.0893 mL | 2.1787 mL | |
| 10 mM | 0.1089 mL | 0.5447 mL | 1.0893 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
